15 results about "Cancer Model" patented technology

The invention relates to a radionuclide labeled trimer probe 68Ga-TRAP-(FAPI) 3 targeting FAP and a preparation method thereof, Trap is used as a trivalent chelating platform, and three FAPI targeting units are covalently connected by clicking a chemical linking arm to form a trimer structure; the invention further relates to application of the 68Ga-TRAP-(FAPI) 3 probe in preparation of imaging agents or therapeutic drugs for diagnosing FAP positive diseases, experiments prove that the trimer probe is good in affinity and high in stability, and in cell experiments and animal experiments, the uptake rate of FAP positive cells is kept at a high level within 240 minutes; preclinical and preliminary clinical applications show that the tumor detection rate of the < 68 > Ga-TRAP-FAPI 3 in various cancer models is superior to that of < 18 > F-FDG, and compared with < 68 > Ga-FAPI-04, the < 68 > Ga-TRAP-FAPI 3 is clearer to display focuses (particularly tiny metastases), higher in uptake intensity and particularly outstanding in delayed imaging, and the < 68 > Ga-TRAP-FAPI 3 can be used for preparing a medicine for treating cancer. And a novel drug candidate with better performance is provided for precise diagnosis and staging of tumors and subsequent radionuclide targeted therapy.

The invention relates to a multi-cancer-species pathological feature analysis method and system based on a unified framework, and belongs to the field of data processing. In the method, a unified multi-cancer-species analysis framework is constructed, a graph network is introduced to formally characterize the cross-cancer-species (such as 16 cancers) pathological feature similarity, and a NOTEARS algorithm is applied to aggregated pathological features to carry out causal discovery, so that the cross-cancer-species pathological feature similarity is found. Therefore, integrated analysis of association and causality of pathological characteristics of multiple cancer species in a unified space can be realized, isolation of a traditional single cancer species model is overcome, and migration and fusion of knowledge among different cancers are promoted. Meanwhile, the group features similar to the target patient are obtained from the graph network for causal analysis, the biological reasonability and stability of causal inference are remarkably improved, the pathological features with the real driving effect can be more reliably identified, and deep analysis of the pathological features is achieved.

The application relates to the technical field of nanomaterials, in particular to an EpCAM aptamer modified nanomaterial and a preparation method and application thereof, wherein the nanomaterial takes carboxylated mesoporous silica nanoparticles as a carrier, and an EpCAM specific DNA aptamer is covalently coupled to the surface of the nanomaterial; the sequence of the EpCAM specific DNA aptamer is shown as SEQ ID No. 1. The nanomaterial can specifically capture tumor-derived exosomes (EVs) in blood, and can realize sensitive detection of EVs in the 7-day (early stage) and 21-day (late stage) stages of an HT29 colon cancer model and the 7-day stage of an A549 / H460 lung cancer model, thereby providing a minimally invasive liquid biopsy new tool for early diagnosis of colon cancer and lung cancer, and solving the inherent limitation problems of sensitivity and specificity of existing diagnosis means in cancer detection.

The invention discloses a method and system for constructing a cancer early screening model based on difference statistics, and belongs to the technical field of cancer model training, and the method specifically comprises the steps: firstly extracting circulating free DNA original features of normal samples and cancer samples, carrying out the clustering screening of the normal samples in a high-cancer proportion cluster after integration, and taking the normal samples as a target group; comparing tree model feature importance analysis between the target group and the remaining normal groups and between the cancer group and the remaining normal groups to obtain a first feature set and a second feature set; obtaining a common feature set, removing the common feature set from the second undetermined feature set to obtain a target feature set, and constructing an initial classification model based on the target feature set; and performing incremental training on each common feature in sequence to obtain a corresponding incremental model and a performance score, and selecting the incremental model with the performance score as a final model, and the method effectively improves the distinguishing ability and generalization performance of the cancer detection model through cluster-guided comparison sample screening and differential feature analysis.

The application discloses a gene editing system for constructing a GP130 gene mutation gastric cancer model pig nuclear transfer donor cell and application thereof. The gene editing system comprises a high-efficiency Cas9 protein prepared according to the method of the application, a high-efficiency target gRNA for the GP130 gene screened, and a single-chain Donor DNA containing a GP130 mutation site, and the optimal use amount ratio of the components of the system is optimized, and finally the single-cell clone ratio of the target site point mutation is 22.5%, which is much higher than the conventional point mutation efficiency (<5%).

The application belongs to the technical field of medicine, and particularly relates to paclitaxel / molybdenum boride nanomaterial and a preparation method and application thereof. 4 / 3 B 2‑x Nanosheet material, the material improves the stability of Mo 4 / 3 B 2‑x Nanosheet by introducing soybean phospholipid, has the characteristics of simple preparation, high drug loading rate and high photo-thermal conversion efficiency. After the nanomaterial loads paclitaxel, as a dual-functional nanodrug for chemotherapy and photo-thermal therapy, when used for lung adenocarcinoma cells, the apoptosis of cancer cells is induced, and the induction effect is better than that of Taxol and Mo 4 / 3 B 2‑x +IR alone. When the nanodrug is applied to a mouse lung cancer model, the growth of the tumor is significantly inhibited, and the inhibition effect is better than that of Taxol and Mo 4 / 3 B 2‑x +IR alone. The results show that the Taxol / Mo 4 / 3 B 2‑x Nanosheet has a synergistic effect when used for lung cancer treatment.

The invention discloses a recombinant bacillus calmette-guerin vaccine medicine for treating bladder cancer, and belongs to the technical field of biological medicine. The recombinant bacillus calmette guerin strain constructed by the invention has a remarkably improved treatment effect on NMIBC, and in a transplanted mouse bladder cancer model and an inducible rat bladder cancer model, the treatment effect of rBCG delta pknG on NMIBC is remarkably superior to that of traditional BCG. Compared with the traditional BCG, the effective rate of the rBCG delta pknG for short-term treatment of NMIBC is increased by 40-50%, and the survival rate of mice is increased by 20%.

The application discloses a kind of based on the construction method and system of cancer early screening model of difference statistics, belong to cancer model training technical field, specifically include: first, the circulating free DNA original feature of normal sample and cancer sample is extracted, and the normal sample in high cancer proportion cluster is filtered after clustering integration as target group;By comparing the tree model feature importance analysis of target group and the remaining normal group, cancer group and the remaining normal group, obtain first feature set and second feature set;Common feature set is acquired, the common feature set is eliminated from the second undetermined feature set, to obtain target feature set, based on the initial classification model of target feature set is constructed;Incremental training is carried out to each common feature in turn, to obtain corresponding incremental model and performance score, and select the incremental model of performance score as final model, the method is compared by clustering guided sample screening and differentiating feature analysis, effectively improve the distinguishing ability and generalization performance of cancer detection model.

The invention provides an antibody specifically binding to human CCR8 or an antigen binding fragment thereof and application thereof. The antibody or the antigen binding fragment thereof provided by the invention can be bound to the surface of a cell expressing CCR8 to block the binding of CCL1-CCR8, and can kill Treg through ADCC, and meanwhile, the antibody or the antigen binding fragment thereof has antitumor activity in a mouse MC38 colon cancer model.

Provided are: a cancer model animal in which a malignant tumor equivalent to the pathological manifestation of human infiltrating cancer or metastasis has been formed or can be formed, despite using subcutaneous or intraperitoneal transplantation; and a method for producing the cancer model animal. One embodiment of the present invention is: a cancer model animal in which tumor cells proliferated in a culture medium containing L-glucose are transplanted subcutaneously or into the abdominal cavity; a sarcoma model animal in which tumor cells transplanted subcutaneously or into the abdominal cavity are infiltrated into muscles; a cancer model animal in which tumor cells such as adenocarcinoma cells transplanted subcutaneously or into the abdominal cavity exhibit metastasis; or tumor cells such as adenocarcinoma cells transplanted subcutaneously or into the abdominal cavity show dysfunction of in-situ cells. Another embodiment of the present invention is a method for producing a cancer model animal, the method comprising a step for transplanting a cell composition into the subcutaneous part or the abdominal cavity of an animal, the cell composition comprising tumor cells cultured and proliferated in a culture medium containing L-glucose, and the method for producing a cancer model animal by being transplanted into the subcutaneous part or the abdominal cavity of the animal.

The invention belongs to the technical field of biological medicines, and particularly relates to application of a PI3Kbeta inhibitor in preparation of a medicine for treating prostatic cancer. According to the application, different types of mouse prostate cancer models are constructed, the PI3Kbeta subtype inhibitor is used as a prostate cancer treatment medicine to treat the mouse prostate cancer models, and the result shows that the PI3Kbeta subtype inhibitor can be used for improving the prostate cancer cold tumor microenvironment by enhancing prostate cancer immune T cell infiltration and T cell function enhancement; therefore, a good anti-tumor effect is achieved; on the other hand, the PI3Kbeta subtype inhibitor does not have adverse reaction in animal bodies, and a new thought is provided for treatment of prostatic cancer.

The application discloses a ctPistol ribozyme and application thereof in gene silencing, and belongs to the technical field of biology.The disclosed ctPistol ribozyme can realize effective control of cell phenotype by silencing the expression of key genes.In addition, when applied in a mouse cancer model, the ctPistol realizes a powerful and persistent anti-tumor effect by targeting oncogenic driver genes.As a powerful gene silencing tool and a promising RNA-based therapeutic candidate drug, the ctPistol ribozyme shows an effective way of developing diversified ribozyme-mediated gene control technology.

The present invention relates to a method for diagnosing gastric cancer or predicting the onset thereof. The present invention also relates to a novel gene variant; a method for preparing a gastric cancer model comprising a genetic mutation; a gastric cancer model comprising the genetic mutation; a composition for diagnosing gastric cancer or predicting the onset thereof; a kit for diagnosing gastric cancer or predicting the onset thereof; and a method for screening a drug for treating or preventing gastric cancer. The method for diagnosing gastric cancer and predicting the onset thereof enables early diagnosis of gastric cancer or prediction and prevention of the risk of gastric cancer occurrence prior to disease onset, thereby significantly reducing the incidence and mortality of gastric cancer. In addition, by observing the presence or absence of genetic mutations or changes in frequency of genetic mutation in response to drug treatment, the method can be utilized for molecular mechanism studies for gastric cancer treatment or for the development of drug screening platforms.

The invention provides an application of 4-bromo-N-(1-methyl-3-(4-methylbenzoyl)-2H-isoindole-2-yl) benzenesulfonamide in preparation of an antitumor drug, and relates to the technical field of biomedicine. The invention provides an excellent potential of 4-bromo-N-(1-methyl-3-(4-methylbenzoyl)-2H-isoindoline-2-yl) benzenesulfonamide (ISO-1 for short) in the aspect of resisting colon cancer, and a cell experiment carried out by a CCK-8 method in the application shows that the ISO-1 has a direct killing effect on colon cancer MC38 cells. In a mouse colon cancer model constructed by MC38 cells, the treatment effect of the ISO-1 is further confirmed. Experimental results show that compared with an untreated Control group, the tumor volume of each group of mice treated by ISO-1 is obviously reduced. The ISO-1 treatment obviously prolongs the lifetime of tumor-bearing mice. The lifetime is one of gold standards for measuring the effectiveness of anti-cancer drugs.

The application provides a construction method and application of a mouse spontaneous tumor model of gastric cancer, and the construction method comprises the following steps: reducing or inhibiting the expression amount of a TP53 gene and / or the activity of a P53 protein in a mouse, and then chemically inducing the mouse by using a drug to obtain a mouse spontaneous tumor model of gastric cancer; wherein the drug comprises sodium nitrite and ethyl sarcosine, and / or the drug comprises an N-nitroso compound. The application first proposes to use NESS to construct a spontaneous gastric cancer model of a C57 mouse, and the construction method of the mouse spontaneous tumor model of gastric cancer provided by the application has a tumor formation rate of 75% or more; the tumor formation cycle is short, about 3-4 months, and the construction cost is low.